Venatorx Pharmaceuticals Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Private

  • Employees
  • 79

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $35M

  • Investors
  • 10

Venatorx Pharmaceuticals General Information

Description

Developer of antibacterial and antiviral drugs designed to treat multi-drug-resistant bacterial infections. The company employs novel chemical approaches to treat multidrug-resistant bacterial infections and hard-to-treat viral infections by developing medicines that exhibit selective and potent in vitro activity against both serine and beta-lactamases, thereby enabling healthcare professionals and doctors to provide patients with access to broad-spectrum treatment options that address unmet medical needs.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 74 East Swedesford Road
  • Suite 100
  • Malvern, PA 19355
  • United States
+1 (610)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 74 East Swedesford Road
  • Suite 100
  • Malvern, PA 19355
  • United States
+1 (610)

Venatorx Pharmaceuticals Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Venatorx Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
15. Later Stage VC 13-Jul-2023 $35M Completed Clinical Trials - Phase 3
14. Later Stage VC (Series C1) 22-Dec-2022 Completed Clinical Trials - Phase 3
13. Later Stage VC (Series C) 04-Apr-2022 Completed Clinical Trials - Phase 3
12. Grant 10-Mar-2022 Completed Clinical Trials - Phase 3
11. Grant 24-May-2021 Completed Clinical Trials - Phase 3
10. Grant 04-May-2021 Completed Clinical Trials - Phase 3
9. Grant 15-Dec-2020 Completed Clinical Trials - Phase 3
8. Grant 05-Sep-2019 Completed Clinical Trials - Phase 3
7. Grant 28-Feb-2019 $22.3M $45.4M Completed Clinical Trials - Phase 3
6. Grant 22-Aug-2018 $1.49M $45.4M Completed Clinical Trials - Phase 3
To view Venatorx Pharmaceuticals’s complete valuation and funding history, request access »

Venatorx Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C-1
Junior
Series C
Series B 348,416 $0.000100 $35.35 $35.35 1x $13.77 4.75%
Series A 146,712 $0.000100 $13.26 $13.26 1x $7.4 1.4%
To view Venatorx Pharmaceuticals’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Venatorx Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of antibacterial and antiviral drugs designed to treat multi-drug-resistant bacterial infections. The company
Drug Discovery
Malvern, PA
79 As of 2024

Aberdeen, United Kingdom
 

Labege, France
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Venatorx Pharmaceuticals Competitors (34)

One of Venatorx Pharmaceuticals’s 34 competitors is NovaBiotics, a Venture Capital-Backed company based in Aberdeen, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NovaBiotics Venture Capital-Backed Aberdeen, United Kingdom
Antabio Venture Capital-Backed Labege, France
Visterra Venture Capital-Backed Waltham, MA
Eligo Bioscience Venture Capital-Backed Paris, France
Enterome Venture Capital-Backed Paris, France
You’re viewing 5 of 34 competitors. Get the full list »

Venatorx Pharmaceuticals Patents

Venatorx Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025111328-A1 Citrate coordination complex of an orally-delivered beta-lactamase inhibitor and uses thereof Inactive 21-Nov-2023
WO-2025106525-A1 Penicillin-binding protein inhibitors Inactive 14-Nov-2023
WO-2024129963-A1 Orally-bioavailable nucleoside analogs Inactive 14-Dec-2022
WO-2023230002-A1 Nlrp3 inflammasome inhibitors Inactive 23-May-2022
US-20250228882-A1 Orally-bioavailable nucleoside analogs Inactive 06-Apr-2022 A61K31/706
To view Venatorx Pharmaceuticals’s complete patent history, request access »

Venatorx Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Venatorx Pharmaceuticals Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
AMR Action Fund Impact Investing Minority
Small Business Innovation Research and Small Business Technology Transfer Programs Government
CARB-X University
Abingworth Venture Capital Minority
Foresite Capital Growth/Expansion Minority
You’re viewing 5 of 10 investors. Get the full list »

Venatorx Pharmaceuticals FAQs

  • When was Venatorx Pharmaceuticals founded?

    Venatorx Pharmaceuticals was founded in 2010.

  • Where is Venatorx Pharmaceuticals headquartered?

    Venatorx Pharmaceuticals is headquartered in Malvern, PA.

  • What is the size of Venatorx Pharmaceuticals?

    Venatorx Pharmaceuticals has 79 total employees.

  • What industry is Venatorx Pharmaceuticals in?

    Venatorx Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Venatorx Pharmaceuticals a private or public company?

    Venatorx Pharmaceuticals is a Private company.

  • What is Venatorx Pharmaceuticals’s current revenue?

    The current revenue for Venatorx Pharmaceuticals is .

  • How much funding has Venatorx Pharmaceuticals raised over time?

    Venatorx Pharmaceuticals has raised $139M.

  • Who are Venatorx Pharmaceuticals’s investors?

    AMR Action Fund, Small Business Innovation Research and Small Business Technology Transfer Programs, CARB-X, Abingworth, and Foresite Capital are 5 of 10 investors who have invested in Venatorx Pharmaceuticals.

  • Who are Venatorx Pharmaceuticals’s competitors?

    NovaBiotics, Antabio, Visterra, Eligo Bioscience, and Enterome are some of the 34 competitors of Venatorx Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process